Therapeutic | Opicinumab |
Target | LINGO1 |
Heavy Chain | EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS |
Light Chain | DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK |
100% seqID Fv Structure | 4oqt [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4oqt [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | Dyax Human Phage Display |
INN Year Proposed | 2015 |
INN Year Recommended | 2106 |
Companies Involved | Biogen Idec, Dyax, Biogen |
Conditions Approved | na |
Conditions Active | Multiple sclerosis, Optic neuritis |
Conditions Discontinued | na |
Notes |